Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.64 |
| ▸ | PKM | P14618 | 3/20 | 0.64 |
| ▸ | MEN1 | O00255 | 3/20 | 0.64 |
| ▸ | LMNA | P02545 | 5/20 | 0.59 |
| ▸ | MAPT | P10636 | 4/20 | 0.59 |
| ▸ | USP2 | O75604 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.56 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.56 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 3/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | NAMPT | P43490 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | MMP13 | P45452 | 1/20 | 0.53 |
| ▸ | GLA | P06280 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4768044 | 0.83 | HPGD (0.52) | KMT2APKMMEN1USP2ALDH1A1 | |
| SCHEMBL5571868 | 0.80 | ALDH1A1 (0.58) | KMT2APKMMEN1LMNAMAPT | |
| SCHEMBL4778580 | 0.79 | SMN1; SMN2 (0.44) | KMT2AMEN1LMNAMAPTHPGD | |
| SCHEMBL4768011 | 0.78 | ALDH1A1 (0.62) | KMT2AMEN1LMNAALDH1A1TDP1 | |
| SCHEMBL4776613 | 0.78 | HIF1A (0.50) | LMNAMAPTHPGDNAMPT | |
| SCHEMBL4775200 | 0.77 | L3MBTL1 (0.47) | LMNAMAPTALDH1A1TDP1HPGD | |
| SCHEMBL4767807 | 0.77 | NPSR1 (0.74) | KMT2APKMMEN1LMNAMAPT | |
| SCHEMBL4772410 | 0.77 | HIF1A (0.55) | KMT2AMAPTALDH1A1HPGDNAMPT | |
| SCHEMBL4791474 | 0.76 | ALDH1A1 (0.61) | KMT2APKMMEN1LMNAMAPT | |
| SCHEMBL4768151 | 0.76 | MAPT (0.49) | KMT2AMEN1MAPTALDH1A1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1942888-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | Cytokinetics, Inc. (US) | 2008-07-16 | — | — | EP | claimed |
| US-20070135435-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INCORPORATED | 2007-06-14 | — | — | US | claimed |
| WO-2007056078-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | CYTOKINETICS, INC. (US) | 2007-05-18 | — | — | WO | claimed |
| EP-1942888-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | Cytokinetics, Inc. (US) | 2008-07-16 | — | — | EP | disclosed |
| US-20070135435-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INCORPORATED | 2007-06-14 | — | — | US | disclosed |
| WO-2007056078-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | CYTOKINETICS, INC. (US) | 2007-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135435-A1 | Certain chemical entities, compositions, and methods | KIF5B, KIF2C, PLK1 | KMT2A 1501/4885PKM 932/4885MEN1 1302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.